Compare Mattel Inc (MAT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs Merck & Co., Inc. — how do they compare? Mattel Inc trades at $16.7 (market cap $4.68B), while Merck & Co., Inc. trades at $142.38 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 75.3× Mattel Inc's market cap, and Merck & Co., Inc. pays a 2.38% dividend while Mattel Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mattel Inc for 97 Days and Merck & Co., Inc. for 98 Days on average.
| MAT | MRK | |
|---|---|---|
Market Cap | $4.68B | $352.29B |
Volume | 11,617,958 | 6,348,796 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.16 | $156.43 |
52-Week Low | $12.66 | $82.49 |
Typical Hold Time | 97 Days | 98 Days |
Enterprise Value | $6.90B | $399.05B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $16.58, up 4.08% on takeover speculation from Authentic Brands Group, with technical indicators showing bullish momentum despite overbought RSI levels. The company maintains solid fundamentals with $5.35B revenue, 7.78% net margin, and attractive valuation at 12.22 P/E ratio. Recent CEO transition to Roger Lynch and potential acquisition interest create significant near-term catalysts.
The stock presents upside potential given the $18 high price target and bullish analyst consensus (53% buy ratings), though execution risks under new leadership and mixed earnings history warrant caution. The takeover premium provides support, but investors should monitor Q3 earnings delivery against the 0.974 EPS expectation for sustained momentum.
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
